Off-label second generation antipsychotics for impulse regulation disorders: a review

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Impulse regulation disorders and substance abuse disorders frequently co-occur with other psychiatric conditions, impacting treatment outcomes.
• Second-generation antipsychotics (SGA) are often used off-label for these conditions, raising concerns about efficacy, dosing, and long-term effects, particularly in pediatric populations.

Purpose of the Study:

• To review the evidence supporting the off-label use of specific SGAs (risperidone, olanzapine, clozapine, ziprasidone, quetiapine, aripiprazole) in impulse regulation and substance abuse disorders.
• To discuss the adverse effects of these agents and explore potential mechanisms of action.

Main Methods:

• Systematic review of double-blind randomized placebo-controlled trials, open-label studies, and case reports.
• Analysis of evidence for risperidone, olanzapine, clozapine, ziprasidone, quetiapine, and aripiprazole in impulse control and substance use disorders.

Main Results:

• Risperidone demonstrated efficacy in attention-deficit/disruptive behavior disorders and tic disorders in children and adolescents. Olanzapine showed efficacy in tic disorders and pervasive developmental disorder. Risperidone and olanzapine were ineffective in substance use disorders.
• Clozapine was ineffective in tic disorders, while ziprasidone was effective. Quetiapine showed no benefit in pervasive developmental disorder. Clozapine, quetiapine, and aripiprazole showed potential benefits in substance abuse and dependence.
• Common side effects include sedation, metabolic issues (hyperglycemia, weight gain, hyperlipidemia), which appear more pronounced in children. Long-term efficacy and safety data are limited.

Conclusions:

• The off-label use of SGAs in impulse regulation and substance abuse disorders yields varied results, with some agents showing promise in specific conditions.
• Further rigorous research, including head-to-head comparisons and long-term studies, is crucial to establish definitive efficacy and safety profiles for these medications in treating these complex disorders.